Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P810031/S083

Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD); Healon Duet PRO II Dual Pack Sodium Hya

Johnson & Johnson Surgical Vision, Inc. · Decision date Oct 30, 2026

MEDTECHLEDGER EXPLANATIONP810031/S083

What did the FDA approve?

FDA records show supplement P810031/S083, tied to PMA P810031, was approved on 2026-10-30 for a design change. The supplied statement names the change as a new cannula design for the Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD).

The supplement scope is limited to use with that OVD in the individual pack and the Healon Duet PRO II Dual Pack. The source does not describe the cannula’s design details, any new indication, or any safety or effectiveness findings; it is a change/design supplement, not a new PMA for the whole system.

FDA approval order statement

approval for a new cannula design for use with the Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD) in both the individual pack and the Healon Duet PRO II Dual Pack
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Ophthalmic
Decision date
Oct 30, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P810031/S083
Regulatory pathway
PMA supplement
Product code
LZP
Decision code
APPR
Decision date
Oct 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: AID, SURGICAL, VISCOELASTIC.

Product code
LZP
FDA device class
3

For the original device and its historical approval scope, see PMA P810031. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P810031 · Original PMA

    HEALON, HEALON GV, HEALON5 PRODUCTS SODIUM HYALURONATE OPHTHALMIC VISCOELASTIC DEVICES

  2. P810031/S083 received

    Application receipt date recorded by FDA.

  3. P810031/S083 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P810031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P810031

Product / regulatory recordCompanyPathwayDecision dateSource
Johnson & Johnson Surgical Vision, Inc.PMA approvalJan 14, 1983FDA

Explore the linked device profile

Other records with product code LZP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Johnson & Johnson Surgical Vision, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records